Neogenomics Inc [NEO] stock is trading at $9.84, up 0.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NEO shares have gain 8.31% over the last week, with a monthly amount drifted -29.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neogenomics Inc [NASDAQ: NEO] stock has seen the most recent analyst activity on January 13, 2025, when The Benchmark Company downgraded its rating to a Hold. Previously, Jefferies started tracking the stock with Buy rating on December 10, 2024, and set its price target to $22. BTIG Research reiterated its Buy rating and decreased its price target to $21 on December 29, 2023. Stephens upgraded its rating to a Overweight but $18 remained the price target by the analyst firm on August 21, 2023. Raymond James downgraded its rating to Mkt Perform for this stock on May 16, 2023. In a note dated May 09, 2023, BTIG Research upgraded an Buy rating on this stock but restated the target price of $25.
Neogenomics Inc [NEO] stock has fluctuated between $8.98 and $19.11 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Neogenomics Inc [NASDAQ: NEO] shares were valued at $9.84 at the most recent close of the market. An investor can expect a potential return of 82.93% based on the average NEO price forecast.
Analyzing the NEO fundamentals
Neogenomics Inc [NASDAQ:NEO] reported sales of 660.57M for the trailing twelve months, which represents a growth of 10.57%. Gross Profit Margin for this corporation currently stands at 0.43% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.09 and Total Capital is -0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.67 points at the first support level, and at 9.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.09, and for the 2nd resistance point, it is at 10.34.
Ratios To Look Out For
For context, Neogenomics Inc’s Current Ratio is 1.98. As well, the Quick Ratio is 1.89, while the Cash Ratio is 1.22. Considering the valuation of this stock, the price to sales ratio is 1.91, the price to book ratio is 1.40.
Transactions by insiders
Recent insider trading involved Olivo Alicia C, General Counsel, that happened on Nov 15 ’24 when 5175.0 shares were sold. Officer, ALICIA OLIVO completed a deal on Nov 15 ’24 to buy 5175.0 shares. Meanwhile, General Counsel Olivo Alicia C sold 1040.0 shares on Aug 15 ’24.
